Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
HTAs Likely to Be Used for Re-Pricing of Listed Medicines
Members of the Central Social Insurance Medical Council (Chuikyo) representing bill payers and healthcare providers agreed on June 24 that cost-effective assessments will be rolled out on a trial basis in FY2016 as a tool to re-price selected drugs already…
To read the full story
Related Article
- FY2016 Drug Pricing Reform
August 18, 2015
- Pay Heed to Company Burdens for Cost-Effective Evaluations, Kamoya Tells Chuikyo
May 28, 2015
- MHLW Eyes Budget Request to Set Up Cost-Effective Analysis Regime, Report Due Out Summer
May 28, 2015
- Thorny Path Ahead toward Trial Rollout of Cost-Effective Assessment in FY2016; Chuikyo to Begin Discussions on May 27
May 26, 2015
- Chuikyo’s HTA Panel Holds First Closed-Door Meeting
January 29, 2015
- Chuikyo’s HTA Panel to Hold Closed Meeting on Jan. 28
January 23, 2015
- Deliberations on Specific Cases of Cost-Effective Assessments to Be Closed to the Public: Chuikyo
December 25, 2014
- Chuikyo at Odds over Disclosure of Cost-Effectiveness Case Study Data to Companies
September 11, 2014
- Chuikyo to Assess Cost-Effectiveness of 5 Listed Drugs, Industry Leery of Price Cuts
May 29, 2014
- Chuikyo Healthcare Provider Rep Vexed by Health Minister Proposal on Use of Drug Cost-Effective Assessment
April 25, 2014
- Trial of Cost-Effective Assessment Should Be Postponed Until FY2016 at Earliest: Expert Subcommittee
December 27, 2013
REGULATORY
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
- Two Bayer/AskBio Gene Therapies Bag Sakigake Designation
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…